We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Delayed Quote USD

IceCure Medical Ltd (ICCM)

1.0000

-0.0400

(-3.85%)

At close: May 14 at 4:00:00 PM EDT

Key Events

Loading Chart for ICCM

Previous Close 1.0400
Open 1.0300
Bid 0.9684 x 200
Ask 1.0600 x 100
Day's Range 1.0000 - 1.0300
52 Week Range 0.4800 - 1.6600
Volume 171,107
Avg. Volume 323,190
Market Cap (intraday) 58.616M
Beta (5Y Monthly) 2.70
PE Ratio (TTM) --
EPS (TTM) -0.3000
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 3.01

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

www.icecure-medical.com

64

Full Time Employees

December 31

Fiscal Year Ends

Sector

Medical Devices

Industry

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

IceCure Medical Full Year 2024 Earnings: Misses Expectations

IceCure Medical Full Year 2024 Earnings: Misses Expectations

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCM

9.09%

S&P 500 (^GSPC)

0.19%

1-Year Return

ICCM

10.71%

S&P 500 (^GSPC)

12.31%

3-Year Return

ICCM

45.05%

S&P 500 (^GSPC)

46.44%

5-Year Return

ICCM

91.58%

S&P 500 (^GSPC)

106.58%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

IceCure Medical Ltd

1.0000

-3.85%

Mkt Cap 58.616M

Industry Medical Devices

10.27

+4.69%

Mkt Cap 193.815M

Industry Medical Devices

Adagio Medical Holdings, Inc.

1.2200

-4.69%

Mkt Cap 18.766M

Industry Medical Devices

Tenon Medical, Inc.

1.1100

-10.48%

Mkt Cap 6.882M

Industry Medical Devices

Xylo Technologies Ltd.

5.05

-1.94%

Mkt Cap 6.469M

Industry Medical Devices

Accelerate Diagnostics, Inc.

0.0340

-61.36%

Mkt Cap 859,917

Industry Medical Devices

Tivic Health Systems, Inc.

4.3200

+7.73%

Mkt Cap 2.679M

Industry Medical Devices

Catheter Precision, Inc.

0.2980

-2.93%

Mkt Cap 2.762M

Industry Medical Devices

Allurion Technologies Inc.

2.9200

+23.73%

Mkt Cap 17.414M

Industry Medical Devices

Beyond Air, Inc.

0.1846

-2.17%

Mkt Cap 15.944M

Industry Medical Devices

INVO Fertility, Inc.

2.0200

+2.02%

Mkt Cap 2.153M

Industry Medical Devices

Valuation Measures

    Annual 

As of 5/14/2025

Market Cap

58.62M
Enterprise Value

51.51M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

15.46
Price/Book (mrq)

8.49
Enterprise Value/Revenue

15.65
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-67.69%
Return on Equity (ttm)

-160.70%
Revenue (ttm)

3.29M
Net Income Avi to Common (ttm)

-15.32M
Diluted EPS (ttm)

-0.3000

Balance Sheet and Cash Flow

Total Cash (mrq)

7.56M
Total Debt/Equity (mrq)

6.65%
Levered Free Cash Flow (ttm)

-7.18M

Earnings Per Share

Consensus EPS

Revenue vs. Earnings

Revenue 875k

Earnings -4.48M

Q1'24

Q2'24

Q3'24

Q4'24

-4M

-3M

-2M

-1M

0

1M

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Analyst Price Targets

2.50

3.01 Average

1.0000 Current

3.53 High

SPRC SciSparc Ltd.

0.3179

-5.61%

PXMD PaxMedica, Inc.

0.0001

0.00%

INBS Intelligent Bio Solutions Inc.

1.2850

-5.51%

HSCS HeartSciences Inc.

3.3400

-1.76%

CDIO Cardio Diagnostics Holdings, Inc.

4.5300

-15.01%

PALI Palisade Bio, Inc.

0.6985

-4.34%

ILAG Intelligent Living Application Group Inc.

0.3790

+4.84%

CMND Clearmind Medicine Inc.

0.9700

-1.02%

INAB IN8bio, Inc.

0.1467

-8.31%

KPRX Kiora Pharmaceuticals, Inc.

3.0866

-3.54%

QNRX Quoin Pharmaceuticals, Ltd.

7.65

+20.28%

WLDS Wearable Devices Ltd.

1.5400

+10.79%

FRGT Freight Technologies, Inc.

1.1300

0.00%

COSM Cosmos Health Inc.

0.4467

-8.65%

VS Versus Systems Inc.

1.8800

-4.57%

TNON Tenon Medical, Inc.

1.1100

-10.48%